These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD; Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841 [TBL] [Abstract][Full Text] [Related]
29. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319 [TBL] [Abstract][Full Text] [Related]
30. A phase 2 study of bortezomib in relapsed, refractory myeloma. Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635 [TBL] [Abstract][Full Text] [Related]
31. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726 [TBL] [Abstract][Full Text] [Related]
32. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652 [TBL] [Abstract][Full Text] [Related]
33. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291 [TBL] [Abstract][Full Text] [Related]
34. Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Roy R; Evens AM; Patton D; Gallot L; Larson A; Rademaker A; Cilley J; Spies S; Variakojis D; Gordon LI; Winter JN Leuk Lymphoma; 2013 Mar; 54(3):497-502. PubMed ID: 22906230 [TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940 [TBL] [Abstract][Full Text] [Related]
36. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674 [TBL] [Abstract][Full Text] [Related]
37. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E; J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550 [TBL] [Abstract][Full Text] [Related]
38. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964 [TBL] [Abstract][Full Text] [Related]
39. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083 [TBL] [Abstract][Full Text] [Related]
40. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]